# EDGAR Filing Document

**Accession Number:** 0001133869
**File Stem:** 0001104659-25-118588
**Filing Date:** 2025-12
**Character Count:** 2917
**Document Hash:** 69d0c5a898bf146248eef53de715e7c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-118588.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001104659-25-118588

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251205

**DATE AS OF CHANGE**: 20251205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CAPRICOR THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001133869
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290179
- **FILM NUMBER:** 251551094

**BUSINESS ADDRESS:**
- **STREET 1:** 10865 ROAD TO THE CURE
- **STREET 2:** SUITE 150
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (310) 358-3200

**MAIL ADDRESS:**
- **STREET 1:** 10865 ROAD TO THE CURE
- **STREET 2:** SUITE 150
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nile Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20070920

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SMI PRODUCTS INC
- **DATE OF NAME CHANGE:** 20010206

**Filed Pursuant to Rule 424(b)(3)**

**Registration No. 333-290179**

![Graphic](capr-20251205x424b3001.jpg)

**PROSPECTUS SUPPLEMENT NO. 1**

**TO PROSPECTUS DATED SEPTEMBER 23, 2025**

This Prospectus Supplement No. 1 supplements and amends the prospectus dated September 23, 2025 (the "Prospectus"), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $150,000,000 (the "Maximum Offering Amount") of our common stock, par value $0.001 per share ("Common Stock"), that may be issued and sold under an equity distribution agreement, dated September 10, 2025, with Piper Sandler & Co. and Oppenheimer & Co. Inc. (the "ATM Facility").

Effective as of December 5, 2025, we have reduced the Maximum Offering Amount to $125,000,000. As of the date of this prospectus supplement, 2,682,307 shares of our Common Stock have been sold under the ATM Facility, for aggregate gross proceeds of approximately $77.5 million, before deducting sales agents' commissions, meaning that we will have approximately $47.5 million remaining available under the Maximum Offering Amount.

You should read this prospectus supplement, together with additional information described under the headings "Information Incorporated by Reference" and "Where You Can Find More Information" in the Prospectus carefully before you invest in our securities.

Investing in our securities involves a high degree of risk. Before making any investment in our securities, you should consider carefully the risks and uncertainties described in the section entitled "Risk Factors" beginning on page S-5 of the Prospectus.

The date of this prospectus supplement is December 5, 2025.

------